ReviewGlobal spine journal2026
Current Trends in Therapeutic Outcomes Among Patients With Metastatic Renal Cell Carcinoma of the Spine: A Systematic Review and Meta-Analysis.
Review in Global spine journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
Abstract
Study DesignSystematic Review.ObjectivesThe objective of this study was to answer two questions: (1) Did the overall survival (OS) of patients with spinal metastatic renal cell carcinoma (mRCC) improve in publications from 2017 and afterwards compared to 2016 and before? (2) Did the rate of improvement in pain or neurological deficits increase in publications from 2017 and afterwards within this population?MethodsA comprehensive search was conducted to include studies that evaluated either survival or clinical outcomes in the spinal mRCC population from 1986 to 2024.Results63 studies encompassing 1,968 patients were included. The mean age was 59.1 years and 70.85% of patients were male. Pain and neurological deficits were the most common presenting symptoms, seen in 37.5% and 36.0% of patients, respectively. Compared with earlier studies, those published during or after 2017 reported improved median OS across spine surgery (27 vs. 12.3 months), radiotherapy (41.3 vs. 10.8 months), and systemic therapy (29.01 vs. 11.45 months) groups. Meta-analysis of 1-year overall survival for patients undergoing spine surgery showed significant improvement from 2017 afterwards (p<0.05). The neurological improvement rate was significantly higher from 2017 afterwards although pain relief did not differ between publication eras.ConclusionsStudies published from 2017 onward report better survival among spinal mRCC patients than earlier studies. Since the analysis is keyed to publication era rather than the therapy each patient received, the contribution of individual modalities cannot be separated, and the improvement likely reflects advances in surgery, radiotherapy, systemic therapy, and patient selection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.